Medcan News

13th January, 2019 – For immediate release

Medcan Australia – Medcan receives it’s Facility Inspection Letter from the Office of Drug Control (ODC)

Medcan Australia (Medcan) is pleased to announce the receipt of it’s Facility Inspection Letter from the Office of Drug Control (ODC).

This Facility Inspection Letter is a summary of the inspection performed by the ODC on the 29th October 2019 and summarizes the outcome of the Medcan facility inspection. The ODC notes “the inspectors found that the rooms inspected provided adequate security measures for cannabis plants and cannabis and cannabis resin”.

Successful issue of this inspection letter is a significant milestone as it is the ODC’s formal advice that the design, construction, security measures, SOP’s and Risk Assessment implemented as part of Medcan’s Cannabis Research Area has been assessed and approved by the ODC.

Comments from Craig Cochran – Managing Director, Founder, Medcan Australia: Medcan Australia Founder, Craig Cochran said: “This is a great achievement for all parties involved as it validates the design, construction and security protocols of our Cannabis Research area within the Medcan facility”. Craig Continued: “This successful approval by the ODC is the culmination of many, many months of hard work and dedication by our entire team. It is testament to the extremely high standard we have set for the design and construction of our facility”.

Background
Medcan Australia was founded in 2016 and was one of the first Australian companies to be licensed by the Office of Drug Control (ODC) to cultivate and produce Medicinal Cannabis, manufacture Medicinal Cannabis products and import and export Medicinal Cannabis products. The company was founded with a single vision to provide Australian patients with high quality, fair priced Medicinal Cannabis products.
Medcan Australia are one of only a few companies in Australia to hold the full suite of ODC (Office of Drug Control) Licences, State Licences & DAWR Permit being:
1) Cultivation and Production Licence – no. MC013/17
2) Manufacture Licence – no. ML015/18
3) Research Licence – no. RL18/19
4) Import Licence – no. 1821087
5) Export Licence – no. 1821088

6) DAWR Permit – no. 0002005875
7) QLD Health Poison’s Licence – no. AG007354718
8) QLD Wholesaling Approval – no. C-MC-1289

Medcan Australia will be producing a range of high quality Medicinal Cannabis strains with varying CBD & THC profiles to suit varying medicinal applications, with all of our products manufactured under GMP certification, ensuring consistent medicine for patients.

For further information on Medcan’s expansion plans: https://www.bluemountcapital.com/MCG/

For Further Information please contact:

Gareth Ball +61414860512 Po Box 4579, Springfield, QLD, Australia, 4300 gareth@medcanaustralia.com.au www.medcanaustralia.com.au

11th of November

10th of October

8th of October 

RAVENQUEST RECEIVES HEALTH CANADA PERMIT FOR EXPORT TO AUSTRALIA       

                                                                                                   

2nd of July 2019

2nd July 2019 Medcan Secured its Research Licence

19th of February 2019

Medcan Looking for new Investors – Press Release FEB 2019.1 (003)